6533b829fe1ef96bd128a34f
RESEARCH PRODUCT
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics
Virginia LiberiniRiccardo LaudicellaMichele BalmaDaniele G. NicolottiAmbra BuschiazzoSerena GrimaldiLeda LorenzonAndrea BianchiSimona PeanoTommaso Vincenzo BartolottaMohsen FarsadSergio BaldariIrene A. BurgerMartin W. HuellnerAlberto PapaleoDésirée Deandreissubject
MaleArtificial intelligencePositron emission tomographyProstate cancerRadiomicsTheragnosticsProstatic Neoplasms610 Medicine & health10181 Clinic for Nuclear MedicineMultimodal ImagingImage Processing Computer-AssistedQuality of Life2741 Radiology Nuclear Medicine and ImagingHumansRadiology Nuclear Medicine and imagingdescription
AbstractIn prostate cancer (PCa), the use of new radiopharmaceuticals has improved the accuracy of diagnosis and staging, refined surveillance strategies, and introduced specific and personalized radioreceptor therapies. Nuclear medicine, therefore, holds great promise for improving the quality of life of PCa patients, through managing and processing a vast amount of molecular imaging data and beyond, using a multi-omics approach and improving patients’ risk-stratification for tailored medicine. Artificial intelligence (AI) and radiomics may allow clinicians to improve the overall efficiency and accuracy of using these “big data” in both the diagnostic and theragnostic field: from technical aspects (such as semi-automatization of tumor segmentation, image reconstruction, and interpretation) to clinical outcomes, improving a deeper understanding of the molecular environment of PCa, refining personalized treatment strategies, and increasing the ability to predict the outcome. This systematic review aims to describe the current literature on AI and radiomics applied to molecular imaging of prostate cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-06-15 |